EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

European Journal of Cancer

Volumn 40, Issue 15, 2004, Pages 2201-2216

  Bokemeyer, C ^a   Aapro, M S ^b   Courdi, A ^c   Foubert, J ^d   Link, H ^e   A Sterborg A ^f   Repetto, L ^g   Soubeyran, P ^h  

^a Medizinische Klinik Abteilung II   (Germany)

^b Inst Multidisciplinaire d'Oncologie   (Switzerland)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d Erasmus Hogeschool   (Belgium)

^e Westpfalz Klinikum GmbH   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Medical Oncology   (Italy)

^h INSTITUT BERGONIÉ   (France)

Author keywords

Anaemia; Cancer; Erythropoietic proteins; Treatment guidelines

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC DISEASE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; HEMATOLOGY; HUMAN; HYPERTENSION; LYMPHOPROLIFERATIVE DISEASE; MEDICAL LITERATURE; MEDICAL PRACTICE; META ANALYSIS; PATHOGENESIS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; PURE RED CELL ANEMIA; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SIDE EFFECT; SOLID TUMOR; STANDARDIZATION; SURVIVAL RATE; THROMBOEMBOLISM; TUMOR GROWTH;

EID: 5344245985     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.07.015     Document Type: Article

References (100)

1. J.M. Koeller Clinical guidelines for the treatment of cancer-related anaemia Pharmacotherapy 18 1998 156 169
2. M.R. Nowrousian, C. Kasper, and C. Oberhoff Pathophysiology of cancer-related anemia J.F. Smyth M.A. Boogaerts B.R.M. Ehmer RhErythropoietin in cancer supportive treatment 1996 Marcel Dekker New York 13 34
3. R.T. Means, and S.B. Krantz Progress in understanding the pathogenesis of the anemia of chronic disease Blood 80 1992 1639 1647
4. M.R. Nowrousian Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours Med. Oncol. 15 Suppl 1 1998 S19 -S28
5. F.-K. Lin, S. Suggs, and C.-H. Lin Cloning and expression of the human erythropoietin gene Proc. Natl. Acad. Sci. USA 85 1985 7580 7584
6. C.G. Winearls, D.O. Oliver, M.J. Pippard, C. Reid, M.R. Downing, and P.M. Cotes Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis Lancet 22 1986 1175 1178
7. H. Ludwig, E. Fritz, H. Kotzmann, P. Hocker, H. Gisslinger, and U. Barnas Erythropoietin treatment of anemia associated with multiple myeloma N. Engl. J. Med. 322 1990 1693 1699
8. J. Vansteenkiste, R. Pirker, and B. Massuti Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J. Natl. Cancer Inst. 94 2002 1211 1220
9. T.J. Littlewood, E. Bajetta, J.W. Nortier, E. Vercammen, and B. Rapoport Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J. Clin. Oncol. 19 2001 2865 2874
10. M. Henke, R. Laszig, and C. Rãbe Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 2003 1255 1260
11. B. Leyland-Jones On behalf of the BEST investigators and study group Lancet Oncol. 4 2003 459 460
12. Sabbattini P. On behalf of the NCCN Anemia Panel. NCCN Clinical Practice Guidelines in Oncology: cancer and treatment-related anemia, version 1.2004. October 28, 2003. Available < http://www.nccn.org/physician_gls/f_guidelines. html
13. J.D. Rizzo, A.E. Lichtin, and S.H. Woolf Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology J. Clin. Oncol. 20 2002 4083 4107
14. J. Glaspy, A.B. Colowick, and A. Heatherington Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life in oncology patients Proc. Am. Soc. Clin. Oncol. 19 2000 54A
15. W. Cheung, N. Minton, and K. Gunawardena Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly Eur. J. Clin. Pharmacol. 57 2001 411 418
16. A.J. Croockewit, M.H. Bronchud, and M.S. Aapro A European perspective on haematopoietic growth factors in haemato-oncology: report of an Expert Meeting of the EORTC Eur. J. Cancer 33 1997 1732 1746
17. American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996, 14, 671-679
18. G. Demetri, M. Kris, J. Wade, L. Degos, and D. Cella Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective study J. Clin. Oncol. 16 1998 3412 3425
19. R.I. Abels, K.M. Larholt, K.D. Krantz, and E.C. Bryant Recombinant human erythropoietin (rHuEPO) for the treatment of anemia in cancer The Oncologist 1 1996 140 150
20. P. Pronzato, E. Cortesi, and C. van der Rijt Early intervention with epoetin alfa in breast cancer patients undergoing chemotherapy: Results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group) Ann. Oncol. 13 Suppl 5 2002 168 [asbtr 620O]
21. H. Thomas, K.F. McAdam, and R.J. Thomas Early intervention with epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy Ann. Oncol. 13 Suppl 5 2002 177 [asbtr 653P]
22. P.M. Wilkinson, H. Andersson, and M. Antonopoulos Early intervention with epoetin alfa treats anaemia and improves quality of life in ovarian cancer patients undergoing chemotherapy Eur. J. Cancer 37 Suppl 6 2001 S264 [abstr 980]
23. F. Dammacco, G. Castoldi, and S. Rodjer Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma Br. J. Hematol. 113 2001 172 179
24. J.U. Blohmer, F. Wãrschmidt, and U. Petry 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer Proc. Am. Soc. Clin. Oncol. 22 2003 447 [abstr 1798]
25. A. Ã-sterborg, Y. Brandberg, and V. Molostova Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies J. Clin. Oncol. 20 2002 2486 2494
26. A. Ã-sterborg, M.A. Boogaerts, and R. Cimino Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study Blood 87 1996 2675 2682
27. M. Boogaerts, B. Coiffier, and C. Kainz Impact of epoetin β on quality of life in patients with malignant disease Br. J. Cancer 88 2003 988 995
28. C. Oberhoff, B. Neri, and D. Amadori Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study Ann. Oncol. 9 1998 255 260
29. D. Kotasek, G. Steger, and W. Faught Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study Eur. J. Cancer 39 2003 2026 2034
30. M. Hedenus, M. Adriansson, and J. San Miguel Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study Br. J. Haematol. 122 2003 394 403
31. J. Seidenfeld, M. Piper, and C. Flamm Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials J. Natl. Cancer Inst. 93 2001 1204 1214
32. G. Iconomou, A. Koutras, A. Rigopoulos, A.G. Vagenakis, and H.P. Kalofonos Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial J. Pain Sympt. Manage. 25 2003 512 518
33. J.A. Sloan, T. Witzig, and P. Silberstein Quality of life, blood transfusions, and toxicity, in anemic patients with advanced cancer receiving weekly erythropoietin while on chemotherapy: results from a phase III randomized double-blind placebo-controlled study Blood 100 2002 287a [abstr 1103]
34. J.F. Bohlius, S. Langensiepen, G. Schwarzer, C.L. Bennett, and A. Engert Does erythropoietin improve overall survival in the treatment of patients with malignant diseases? Results of a comprehensive meta-analysis Blood 102 2003 203a [abstr 709]
35. C. Wurnig, R. Windhager, and E. Schwameis Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study) Transfusion 36 1996 155 159
36. G. Mantovani, M. Ghiani, and L. Curreli Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients Oncol. Rep. 6 1999 421 426
37. J. Janinis, U. Dafni, and G. Aravantinos Quality of life outcome of epoietin-alfa in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: a randomized study conducted by the Hellenic Cooperative Oncology Group Proc. Am. Soc. Clin. Oncol. 22 2003 789 [abstr 3172]
38. O. Clark, J. Adams, C. Benett, and B. Djulbegovic Erythropoietin, uncertainty principle and cancer-related anaemia BMC Cancer 2 2002 23
39. B. Glimelius, T. Linne, and K. Hoffman Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer J. Clin. Oncol. 16 1998 434 440
40. F.R. Rosen, D.J. Haraf, and M.S. Kies Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer Clin. Cancer Res. 9 2003 1689 1697
41. M. Cazzola, Y. Beguin, J. Kloczko, I. Spicka, and B. Coiffier Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production Br. J. Haematol. 122 2003 386 393
42. M. Hedenus, S. Hansen, and K. Taylor Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies Br. J. Haematol. 119 2002 79 86
43. J.A. Glaspy, J.S. Jadeja, and G. Justice Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy Br. J. Cancer 87 2002 268 276
44. J.A. Glaspy, J.S. Jadeja, G. Justice, A. Fleishman, G. Rossi, and A.B. Colowick A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease Cancer 97 2003 1312 1320
45. M. Tsukuda, S. Yuyama, H. Kohno, K. Itoh, T. Kokatsu, and S. Kawai Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia Biotherapy 11 1998 21 25
46. M. Zagari, M. Wacholtz, and L. Xiu An open-label, controlled, randomized, dose comparison study of epoetin alfa for the treatment of anemia in cancer patients receiving platinum-containing chemotherapy Hematol. J. 4 Suppl 2 2003 61 [abstr 0177]
47. P. Pantellakos, D. Mouratidou, and G. Georgacopoulos Effects of erythropoietin on cancer patients undergoing radiotherapy (Hellenic Group for Clinical Radiation Oncology) Ann. Oncol. 13 Suppl 5 2002 178 [abstr 654P]
48. S. Cloutier, F.A. Tetu, J. Poulin, C.Y. Lau, and G. Cantin Evaluation of recombinant human erythropoietin (epoetin alfa) and autologous blood donation in breast reconstruction with transverse rectus abdominus myocutaneous (TRAM) flap after mastectomy for breast cancer Proc. Am. Soc. Clin. Oncol. 22 2003 773 [abstr 3106]
49. F. Dunphy, T. Dunleavy, and B. Harrison Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin Cancer 79 1997 1623 1628
50. N. Kosmadakis, E. Messaris, and A. Maris Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study Ann. Surg. 237 2003 417 421
51. N. Qvist, S. Boesby, B. Wolff, and C.P. Hansen Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: reduced need for blood transfusions in patients undergoing colorectal surgery: prospective double-blind placebo-controlled study World J. Surg. 23 1999 30 35
52. M. Braga, L. Gianotti, O. Gentilini, A. Vignali, L. Corizia, and V. Di Carlo Erythropoiesis after therapy with recombinant human erythropoietin: a doseâ€"response study in anemic cancer surgery patients Vox Sang 76 1999 38 42
53. C. Kettelhack, C. Hones, D. Messinger, and P.M. Schlag Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma Br. J. Surg. 85 1998 63 67
54. M.M. Heiss, A. Tarabichi, and C. Delanoff Perisurgical erythropoietin application in anemic patients with colorectal cancer: a double-blind randomized study Surgery 119 1996 523 527
55. S.N. Scott, T.J. Boeve, T.M. McCulloch, K.A. Fitzpatrick, and L.H. Karnell The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study Laryngoscope 112 2002 1221 1229
56. M. Braga, L. Gianotti, O. Gentilini, A. Vignali, L. Corizia, and V. Di Carlo Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery Hepato- gastroenterology 44 1997 685 690
57. I. Quirt, C. Robeson, and C.Y. Lau Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy J. Clin. Oncol. 19 2001 4126 4134
58. R.E. Smith Jr, N.S. Tchekmedyian, and D. Chan A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer Br. J. Cancer. 88 2003 1851 1858
59. G.A. Pangalis, M.P. Siakantaris, and M.K. Angelopoulou Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin Haematologica 87 2002 500 506
60. J.E. Johansson, P. Wersall, Y. Brandberg, S.O. Andersson, and L. Nordstrom EPO-Study Group. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer: a randomized study Scand. J. Urol. Nephrol. 35 2001 288 294
61. P. Daneryd, E. Svanberg, and U. Korner Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomised prospective study Cancer Res. 58 1998 5374 5379
62. M. Marinaccio, E. Mele, F. Giotta, C. Cantinieri, and M. Cocca Pretreatment normalization of mild anemia with epoetin alfa: impact on the outcome in epithelial ovarian cancer patients Proc. Am. Soc. Clin. Oncol. 22 2003 486 [abstr 1952]
63. F. Ribiero Gomes, A. Marques, and O. Costa Erythropoietin therapy: is there a place in advanced prostate cancer-related anemia Eur. J. Cancer 37 Suppl 6 2001 S222 [abstr 813]
64. P. Niscola, L. Scaramucci, V. Bongarzoni, and M. Montanaro Management of disease-related anemia by high-doses of epoetin alfa in patients with multiple myeloma Blood 100 2002 387b [abstr 5111]
65. A. Pappalardo, D. Giuffrida, and S. Castorina Epoetin alfa (100,000 U in 8 consecutive days) in treatment of anemic “home care patients with advanced cancer Proc. Am. Soc. Clin. Oncol. 22 2003 786 [abstr 3160]
66. M.J. Mauro, C. Blasdel, M. O'Dwyer, G. Kurilik, R. Capdeville, and B. Druker Erythropoietin for anaemia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy Proc. Am. Soc. Clin. Oncol. 21 2002 27a [abstr 106]
67. A. Bamias, G. Aravantinos, and C. Kalofonos Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEPO): a prospective, open label, randomised trial by the Hellenic Cooperative Oncology Group Oncology 64 2003 102 110
68. J. Crawford, F. Robert, M. Perry, C.P. Belani, and B. Sarokhan for the Anemia Prevention in NSCLC Study Group. Epoetin alfa 40,000 U once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy Proc. Am. Soc. Clin. Oncol. 22 2003 628 [abstr 2527]
69. J. Chang, and F. Couture For Canadian Eprex Study Group. Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy Proc. Am. Soc. Clin. Oncol. 22 2003 727 [abstr 2923]
70. L. Del Mastro, M. Venturini, and R. Lionetto Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia J. Clin. Oncol. 15 1997 2715 2721
71. W.W. ten Bokkel Huinink, C.A. de Swart, and D.W. van Toorn Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy Med. Oncol. 15 1998 174 182
72. N. Thatcher, E.S. De Campos, and D.R. Bell Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer Br. J. Cancer 80 1999 396 402
73. T.H. Chiang, J. Fastenau, and F.J. Papatheofanis Erythropoietic agents for the prevention of cancer-related anemia: a systematic review and meta-analysis of clinical trials Proc. Am. Soc. Clin. Oncol. 22 2003 557 [abstr 2241]
74. V. Moebus, G. Bastert, and R. Kreienberg Epoetin alpha prevents anemia and transfusions of RBCs in patients receiving dose-dense sequential chemotherapy Proc. Am. Soc. Clin. Oncol. 20 2001 10a [abstr 36]
75. F. Dunphy, B. Harrison, T. Dunleavy, J. Rodriguez, J. Hilton, and J. Boyd Erythropoietin reduces anemia and transfusions, a randomised trial with or without erythropoietin during chemotherapy Cancer 86 1999 1362 1367
76. R.S. Welch, R.D. James, P.M. Wilkinson, F. Belli, and R.A. Cowan Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer Cancer J. Sci. Am. 1 1995 261 266
77. P.J. Sweeney, D. Nicolae, and L. Ignacio Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial Br. J. Cancer 77 1998 1996 2002
78. M. Henke, R. Guttenberger, A. Barke, F. Pajonk, R. Potter, and H. Frommhold Erythropoietin for patients undergoing radiotherapy: a pilot study Radiother. Oncol. 50 1999 185 190
79. S. Klaesson, O. Ringden, P. Ljungman, B. Lonnqvist, and L. Wennberg Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin Bone Marrow Transpl. 13 1994 397 402
80. S. Filip, J. Vanasek, M. Blaha, P. Mericka, J. Vavrova, and K. Podzimek The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients Neoplasma 46 1999 166 172
81. N.J. Chao, J.R. Schriber, and G.D. Long A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation Blood 83 1994 2823 2828
82. A.A. Fauser, L. Kraut, M.G. Kiehl, and N. Basara A prospective randomized clinical trial with erythropoietin-alfa in patients undergoing unrelated stem cell transplantation Blood 100 2002 839a [abstr 3313]
83. J.C. Biggs, K.A. Atkinson, and V. Booker Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors Bone Marrow Transpl. 15 1995 129 134
84. H. Link, M.A. Boogaerts, and A.A. Fauser A controlled trial of recombinant human erythropoietin after bone marrow transplantation Blood 84 1994 3327 3335
85. A.M. Vannucchi, A. Bosi, and S. Linari High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study Haematologica 82 1997 53 56
86. A.M. Vannucchi, A. Bosi, and A. Ieri Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial Bone Marrow Transpl. 17 1996 527 531
87. L. Pierelli, G. Scambia, and G. Menichella The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation Br. J. Haematol. 92 1996 287 294
88. M. Martino, M. Morabito, and M. Fujo A treatment with R-HuEPO after mobilization procedure and before high-dose-chemotherapy and autologous peripheral blood stem cell transplant decrease anemia in patients with multiple myeloma Hematol. J. 3 Suppl 1 2002 38 [abstr 0087]
89. L.J. Ayash, A. Elias, and M. Hunt Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation Br. J. Haematol. 87 1994 153 161
90. C. Granetto, S. Ricci, and A. Martoni Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin α in anemic cancer patients receiving platinum-based chemotherapy Oncol. Rep. 10 2003 1289 1296
91. P.J. Hesketh, F. Arena, and D. Patel Front-loaded darbepoetin alfa with Q3W maintenance administered as a fixed or weight-based dose in anemic cancer patients results in similar efficacy profiles Proc. Am. Soc. Clin. Oncol. 22 2003 731 [abstr 2941]
92. D.W. Blayney, H. Spiridonidis, and M.R. Fesen Darbepoetin alfa every 2 weeks to treat chemotherapy-induced anemia: Experience in a randomized, open-label study Proc. Am. Soc. Clin. Oncol. 22 2003 747 [abstr 3003]
93. A.C. Heatherington, J. Schuller, and A.J. Mercer Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report Br. J. Cancer 84 Suppl 1 2001 11 16
94. J. Crawford, D. Cella, and C.S. Cleeland Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 2002 888 895
95. V. Brower Erythropoietin may impair, not improve, cancer survival Nat. Med. 9 2003 1439
96. N. Casadevall, J. Nataf, and B. Viron Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N. Engl. J. Med. 346 2002 469 475
97. N. Casadevall Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin Nephrol. Dial. Transpl. 18 Suppl 8 2003 VIII37 -VIII41
98. S. Hermeling, H. Schellekens, D.J.A. Crommelin, and W. Jiskoot Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity Pharm. Res. 20 2003 1903 1907
99. I.C. Macdougall Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another Curr. Med. Res. Opin. 20 2004 83 86
100. L. Quint, N. Casadevall, and S. Giraudier Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins Br. J. Haematol. 124 2004 836 844